MedTrace Logo

Seroprevalence and Immunoprotection Against COVID-19 in Parisian Children

NCT04490811 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2020-07-29

No results posted yet for this study

Summary

The paediatric population present mild or asymptomatic form of SARS-CoV-2 infection. This study asses the frequency of patients with SARS-CoV2 Antibodies (Ab) (seroprevalence) and the neutralizing typology of those Ab (immunoprotection) in children from 7 days to 18 years of age hospitalized for no more than 4 days and whose clinical status requires blood sample regardless of the symptoms Patients are included on a given day, after information, before blood sampling performed as part of the care. 500 µL of sera, normally discarded will be kept to perform SARS-Cov2 serology.

Conditions

Interventions

OTHER

no intervention. observational cohort study

blood sampling is part of care

Sponsors & Collaborators

  • Hôpital Necker-Enfants Malades

    lead OTHER

Eligibility

Min Age
7 Days
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04490811 on ClinicalTrials.gov